Tackling Emerging Co-Infections

应对新出现的合并感染

• 批准号: MC_PC_21021
• 负责人: Gordon Brown
• 金额: $ 25.48万
• 依托单位: UNIVERSITY OF EXETER
• 依托单位国家: 英国
• 项目类别: Intramural
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MC_PC_21021
• 关键词: Tackling; Emerging; Co; Infections; Tackling; Emerging; Co; Infections

Humans are continuously exposed to multiple pathogens yet, with the exception of a few well defined coinfection scenarios (HIV and tuberculosis for example), relatively little is known about the impact of co-infections on morbidity and mortality. There is growing evidence indicating that co-infections are common, exacerbate disease severity and can considerably worsen outcome (Influenza or COVID-19 associated Aspergillus infection for example). Co-infections with drug-resistant pathogens have shown to add another layer of complexity with high case-fatality rates. Our aim is to integrate and exploit the expertise of four Centres that are tackling the major pathogen groups [viruses, bacteria, fungi and parasites] to promote UK-wide research on the pathophysiological impact and mechanistic basis of disease in co-infections.

除了一些明确定义的共感染场景（例如，HIV和结核病）外，人类持续暴露于多种病原体，对共同感染对发病率和死亡率的影响相对鲜为人知。越来越多的证据表明，共同感染是常见的，加剧了疾病的严重程度，并且可能会严重恶化（例如，流感或Covid-19相关的曲霉感染）。与药物耐药病原体的共感染已证明可以增加另一层复杂性，并具有高病态率。我们的目的是整合和利用四个中心的专业知识，这些中心正在应对主要的病原体群体[病毒，细菌，真菌和寄生虫]，以促进整个英国范围内有关疾病感染中疾病的病理生理影响和机械基础的研究。